PCKS9 Inhibitors Seen Driving Down LDL-C in Diabetes

Published Date: 30 Mar 2026

A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot